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ABSTRACT
The aetiological diagnosis of pneumoniadepends largely on culture-, antigen- or PCR-based tests.Atypical
agents of pneumonia include Coxiella burnetii, Chlamydophila pneumoniae, Chlamydia psittaci, Legionella
pneumophila, Francisella tularensis and Mycoplasma pneumoniae. In these cases, serological tests are
commonly used for diagnosis. All of the above species were comparatively screened for by using the
InoDiag multiplexed automatic immunoﬂuorescence assay and established reference techniques. The
InoDiag assay required 5 lL of serum, took 76 min per serum sample, and required an incubator, a
ﬂuorescence reader and interpretation software. In total, 248 single sera from patients were tested, for the
diagnosis of pneumonia, and the results obtainedwith selected serumsampleswere comparedwith results
obtained with the reference method. It was shown that, for the detection of Coxiella burnetii IgM, the
automated assay had a sensitivity and speciﬁcity of 100%. For the detection of M. pneumoniae IgM,
sensitivitywas 100% and speciﬁcitywas 98%. For thedetection ofChlamydophila pneumoniae andChlamydia
psittaci IgG, sensitivitywas 81% and speciﬁcitywas 94%. For the detection of L. pneumoniae IgG, sensitivity
was 63% and speciﬁcity was 98%. For the detection of F. tularensis IgG and IgM, sensitivity was 100% for
both, and speciﬁcity was 95% and 100%, respectively. The performance of this serological assay was
comparable to that of other assays reported in the literature. This preliminary study shows that the
automatic InoDiag assay opens the way to immunoﬂuorescence assay standardization.
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INTRODUCTION
The aetiological diagnosis of community-acquired
pneumonia (CAP) is usually based on clinical and
laboratory ﬁndings. Microbiological tests are per-
formed, not to narrow treatment options, but to
provide more conﬁdence in the selected treat-
ment. Indeed, a causative pathogen is identiﬁed
in 20–50% of cases [1]. So-called atypical pneu-
monias represent c. 15% of cases of CAP [2], and
the principal aetiological agents are Coxiella
burnetii, Chlamydophila pneumoniae, Chlamydia psit-
taci, Legionella pneumophila, Francisella tularensis
and Mycoplasma pneumoniae. Culturing of the
agent is rarely performed for diagnosis of these
infections, because of the fastidious growth of the
causative organisms and the biohazard conditions
that they can create. Other useful direct methods
for the detection of microorganisms include anti-
gen detection tests, DNA probes, and ampliﬁca-
tion tools. For example, in cases of severe CAP,
detection of L. pneumophila serogroup 1 antigen
in a patient’s urine is recommended for diagnosis
[3]. A negative urinary antigen test result does not
exclude the diagnosis, particularly if the antigen
stems from organisms other than L. pneumophila
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serogroup 1. However, a positive test result is
diagnostic of infection [4]. With regard to other
methods, PCR tools provide rapid techniques for
the accurate diagnosis of C. pneumoniae and
M. pneumoniae, both of which can be identiﬁed
by this method from a single throat swab [5,6]. In
addition, many other protocols have been devel-
oped to detect such atypical bacteria, even respi-
ratory viruses. However, the role of these new
tools is under investigation, and recommenda-
tions cannot be made until the performances of
these new tools have been clariﬁed.
Serological testing has limited applications in
the routine management of CAP. As the determi-
nation of antibody levels in both acute and
convalescent sera is required before ascribing
clinical disease to one of these pathogens [7],
serological testing is usually not helpful in the
early management of CAP. However, in cases of
atypical pneumonia, serology is the most reliable
technique for the aetiological diagnosis of
F. tularensis and Coxiella burnetii. A serum sample
is also the easiest specimen to collect in the case of
C. pneumoniae, Legionella sp. and M. pneumoniae
infection. Serology is controversial; however, it
could be used, not only as an alternative in the
primary screening of pneumonia, but also in
epidemiological studies.
The most common serological method, the
indirect immunoﬂuorescence assay (IFA), is used
to detect antibodies against bacterial agents
responsible for atypical pneumonia, including
L. pneumophila, Coxiella burnetii, C. pneumoniae,
Chlamydia psittaci and F. tularensis. IFA incorpo-
rates the whole organism as the antigen, and
the ﬂuorescence measured is proportional to the
antibody concentration. The detection and the
quantiﬁcation of different immunoglobulin clas-
ses (IgG, IgM, IgA) can be performed using
different ﬂuorochromes. However, ﬂuorescence
reading is susceptible to human subjectivity, and
another problem arises in the difﬁculty of inter-
pretation when there are non-speciﬁc reactions.
IFA is poorly reproducible among laboratories
and even within the same laboratory, as demon-
strated in the serological diagnosis of Lyme
disease [8]. Overall, IFA continues to be a labo-
rious and time-consuming technique. Another
method that is widely employed to detect anti-
bodies is ELISA, a useful technique combining
simplicity and sensitivity, which is used in epi-
demiological studies and for the diagnosis of
numerous infectious diseases. This technique can
be reliably used for the screening of large panels
of samples for a variety of infectious agents. An
ELISA is easy to perform, adaptable, and com-
monly used for the diagnosis of C. pneumoniae [9]
and M. pneumoniae [10]. However, depending on
the speciﬁcity of the antigen used, false-positive
results can be obtained with varying frequencies.
Another potential problem with this technique is
the prozone effect, which refers to an unexpected
drop in signal strength when the antibody to be
assessed is present in very large quantities.
Finally, the volume of serum required for each
test may be a limiting factor when performing
multiple ELISA tests with a single sample.
Serological criteria are available for all of the
techniques commonly used [3,11]. Indeed, two
serum samples collected within an interval of 3
or 4 weeks are used as serological evidence of an
ongoing infection. A four-fold increase in titres
of IgG, IgG plus IgM and ⁄ or the appearance of
IgM antibodies during the evolution of the
disease episode and ⁄ or the appearance of IgM
antibodies during the evolution of the disease
are used as diagnostic criteria. But, IgM detec-
tions are usually less sensitive and speciﬁc than
four-fold changes in IgG antibody titres between
paired specimens taken at intervals of several
weeks.
Antigen microarrays have been used for simul-
taneous determination of antibodies in human sera
directed against Toxoplasma gondii, rubella virus,
cytomegalovirus, and herpes simplex virus
types 1 and 2. This technique determines the
presence or the absence of speciﬁc IgG and IgM
in the sera [12,13]. Its beneﬁts include multiple
simultaneous protein measurements, rapid exper-
iments and analysis, quantitative and sensitive
detection, and low volume requirements. The
development of a protein microarray could pro-
vide many advantages in the determination of
speciﬁc aetiological pathogens of CAP. This mul-
tiplexed serology test would facilitate the screen-
ing of the serological patient status and would
providemore conﬁdence in the effectiveness of the
treatment regimen. Multiplexed slides for manual
IFA are available for serological diagnosis of
infectious diseases (Euroimmun, Lu¨beck, Ger-
many). InoDiag (La Ciotat, France) has currently
developed a one-step, fully automated multi-
plexed IFA, including slide reading and serolog-
ical interpretation.
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The objective of this study was to compare the
fully automated InoDiag assay and the reference
IFA and ELISA techniques used in the authors’
laboratory for the detection of antibodies against
11 pathogens responsible for atypical pneumonia:
Coxiella burnetii, M. pneumoniae, C. pneumoniae,
Chlamydia psittaci, L. pneumophila serotypes 1–6,
and F. tularensis.
MATERIALS AND METHODS
Patients and controls
In order to compare the performance of the InoDiag assay with
that of the reference techniques used (see below), sera from
patients suffering from pneumonia caused by a previously
identiﬁed causative agent were selected.
Patients with atypical pneumonia were diagnosed between
April 2000 and December 2005, using clinical, epidemiological
and serological criteria. The sera were collected 1–20 days after
the onset of the acute disease from patients with clinical
symptoms of pneumonia admitted to la Timone Hospital,
Marseilles, France.
The laboratory in which the study took place is the French
national reference centre for Coxiella burnetii, and therefore in-
house IFA slides for the serological diagnosis of Coxiella
burnetii [14] were used. Positive serum samples of 23 patients
suffering from Coxiella burnetii infection with a diagnostic
criterion of IgM ‡100 (n = 19) or a seroconversion (n = 4) were
used.
When studying F. tularensis, the serological diagnosis of
tularaemia was performed routinely, using IFA in-house slides
[15]. Sixteen positive sera obtained from patients with acute
F. tularensis infection were selected, and the following criteria
were used: IgM ‡200 (n = 10) or a four-fold rise in titre
between acute-phase and convalescent-phase sera (n = 6) in
patients with typical tularaemia.
For Legionella sp., positive serum samples obtained from
patients with acute pneumonia sent to the laboratory at la
Timone Hospital and also to the French national reference
centre (courtesy of J. Etienne, Lyon, France) were used.
Serology was performed using commercial IFA slides for
L. pneumophila serogroup 1–6 (Virotech, Ru¨sselsheim, Ger-
many) [16]. The sera were selected according to the following
diagnostic criteria: for acute L. pneumophila infection, serocon-
version (n = 11) and ⁄ or positive L. pneumophila antigenuria or
IgG ‡256 in sera from convalescent patients (obtained from
the national reference centre) with compatible clinical symp-
toms (n = 8). Sera obtained from patients with L. pneumophila
infection (serogroup 1 (n = 6), serogroup 2 (n = 2), sero-
group 3 (n = 3), serogroup 5 (n = 4), and serogroup 6
(n = 4)) were tested.
For Chlamydia sp. infection, sera obtained from patients
with acute pneumonia received at the la Timone Hospital
laboratory and at the French national reference centre (cour-
tesy of C. Bebear, Bordeaux, France) were used. Serology was
performed using commercial IFA slides for C. pneumoniae and
Chlamydia psittaci (Virotech) [17]. For acute C. pneumoniae
infection, sera were selected according to the following
criteria: seroconversion (n = 4) or convalescent-phase sera
obtained from the national reference centre with IgG ‡256
(n = 6). For Chlamydia psittaci, one acute infection serum was
obtained from the national reference centre with an IgG titre
‡256.
For M. pneumoniae, sera received at the Timone Hospital
laboratory that were obtained from patients with acute
pneumonia were used. Serology was performed using ELISA
(Meridien, Cincinnati, OH, USA) [18]. Nineteen sera were
selected according to the following diagnostic criteria:
IgM ‡1.2 and patient age £30 years (n = 10) or seroconversion
(n = 5), and convalescent-phase serum (n = 4).
The control group consisted of 160 serum samples obtained
from hospitalized patients with pneumonia, but without
aetiological diagnosis, and who tested negative according to
reference techniques for the above-listed microorganisms.
Controls were evaluated by systematic initial testing per-
formed at the time of admission and before any antibiotic
treatment. Sera from patients and controls were tested using
the same method as described above.
InoDiag slides
The automatic IFA developed by InoDiag was based on spots
of 5 nL of antigen deposited onto glass slides with an
Afﬂymetrix arrayer 417 spotter. Slides were analysed using a
ﬂuorescent camera analyser, allowing the simultaneous detec-
tion of IgG and IgM directed against all antigens tested. Each
multiplexed slide contained four controls and 11 antigens. The
four controls used were: Staphylococcus aureus ATCC 29213 to
verify serum deposition [19], human IgG (Serotec, Oxford, UK)
to verify the secondary antibody distribution and to detect the
presence of rheumatoid factor in patient sera, human IgM
(Sigma, St Quentin Fallavier, France) to verify the secondary
antibody distribution, and double-stranded DNA (Diarect,
Freiburg, Germany) to detect antinuclear antibodies in patient
sera. The multiplexed slide included nanolitre spots containing
each of the following antigens: C. pneumoniae (ATCC VR-
1310), Chlamydia psittaci (ATCC VR-601), L. pneumophila
serogroup 1–6 (ATCC 33152, ATCC 33154, ATCC 33155,
ATCC 33156, ATCC 33216 and ATCC 33215), Coxiella
burnetii phase I and II (Nine Mile strain, ATCC VR-616), and
F. tularensis (clinical isolate [15]).
Automated immunoﬂuorescence assay
Four serum samples could be tested at one time. Each patient
serum was diluted 1 : 16 (5 lL of serum was diluted in 75 lL
of phosphate-buffered saline), and 50 lL of diluted serum was
distributed in the circular steel chamber of the InoDiag
incubator. When the InoDiag slides were clamped over the
chamber, contact between the serum sample and the slide
occurred with an incubation time of c. 1 h. All remaining IFA
reaction steps, including serum incubation, washing and
drying, and secondary antibody addition and incubation, were
fully automated. Brieﬂy, the assay included a 20-min incuba-
tion of the diluted serum at room temperature, three 5-min
washes (total = 15 min) with phosphate-buffered saline (con-
taining 0.5% sodium azide and 10% goat serum (Jacques Boys,
Reims, France)), 20 min of incubation with the secondary
ﬂuorescein isothiocyanate-conjugated antibody (Beckman
Coulter, Marseille, France) and Texas red (Interchim, Mon-
luc¸on France), and three additional washes as described above.
Slides were then rinsed with de-ionized water for 1 min, and
air-dried for 5 min.
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Slide reading and interpretation
The dried slide was analysed by an automatic InoDiag
ﬂuorescent camera analyser after exposure at wavelengths of
365, 470 and 594 nm, for 0.2 ms each. Arbitrary unit values
(AUV) were automatically assigned for each spot using the
data-processing software Analarray 4.4-1 (InoDiag). Reading
at 365 nm determined the presence of all antigens in the spots
and their respective surfaces.
Reading at 470 nm measured the ﬂuorescence surface of
each antigen spot based on the 365-nm view. The ﬂuorescence
signal of a deﬁnite area was converted into a grey-scale pixel
image for the detection and quantiﬁcation of IgG (Fig. 1).
Normalization was done by using the coefﬁcient of the IgG
spot ﬂuorescence value ⁄ IgM spot ﬂuorescence value.
Reading at 594 nm in order to detect IgM, and to determine
speciﬁcally its concentration, was automatically performed by
the method described above for the reading at 470 nm.
The analysis was validated when all the spots were detected
after the reading at 365 nm and when the ﬂuorescence levels of
control spots, read at 470 and 594 nm, were determined.
When the ﬂuorescence of the S. aureus spot read at 470 nm
was >20 000 AUV, serum deposit was validated. When the
ﬂuorescence of the human IgG spot read at 470 nm was
>15 000 AUV and IgM was read at 594 nm was >6000 AUV,
the secondary antibody deposit and quality were conﬁrmed.
Negative controls allowed for detection of rheumatoid factor
and antinuclear antibodies, which may cause false-positive
results during IFA. When the ﬂuorescence of the double-
stranded DNA spot read at 470 nmwas >1300 AUVwhen read
for the IgGﬂuorescenceandwas>750 AUVwhenreadat594 nm
for the IgM ﬂuorescence, antinuclear antibodies were detected.
When the ﬂuorescence of the human IgG spot read at
594 nm was >3500 AUV, rheumatoid factor was considered to
be present. In this way, internal controls deposited on each
slide allowed for the technical validation, control of the serum
and the conjugate distribution, and of the presence of rheu-
matoid factor and antinuclear antibodies.
To determine the reproducibility of the detection of each
antigen, three sera were selected and tested successively ﬁve
times with the InoDiag method.
Statistical analysis
The three InoDiag cut-off values were chosen in order to
obtain the highest sensitivity and negative predictive value
(NPV) for the ﬁrst cut-off value and the highest speciﬁcity
and positive predictive value (PPV) for the third cut-off
value. The medium cut-off value was chosen to select a grey
zone. The sensitivity, speciﬁcity, PPV and NPV were calcu-
lated, based on all 248 samples, using the routine techniques
(manual IFA and ELISA) as references, and compared, with
respect to each antigen, with the values obtained with the
InoDiag method.
The formula used to determine sensitivity comprised the
true positives (TP) divided by the sum of the TP and the false
negatives (FN): (TP ⁄ (TP + FN)). The formula used to deter-
mine speciﬁcity comprised the true negatives (TN) divided
by the sum of the TN and the false positives (FP):
(TN ⁄ (TN + FP)). The PPV of a test is the chance that a patient
with a positive test result actually has the disease or infection
that the test is meant to detect; PPV = TP ⁄ (TP + FP). The NPV
of a test is the chance that a patient with a negative test result
actually does not have the disease or the infection that the test
is meant to detect; NPV = TN ⁄ (TN + FN). Testing was per-
formed for IgG and ⁄ or IgM for each antigen. In order to
determine the correlation between the the results obtained
with the automated technique and the reference techniques, a
Pearson correlation coefﬁcient was determined for each anti-
gen using Microsoft Excel 2003.
The Pearson coefﬁcient was considered to be signiﬁcant
when p <0.05. For M. pneumoniae IgM detection, the patient’s
age limit of <30 years was used in order to avoid false-negative
and false-positive results, as it has been shown that 80% of
patients aged 21–40 years exhibit speciﬁc IgM [20].
RESULTS
Slide validation
Ten (4%) of the 248 slides tested were rejected
because of serum omission (lack of serum deposit
1 2 3 4
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1 3
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Fig. 1. Serum of a patient with acute Q-fever. Pneumonia slide analysed by a ﬂuorescent camera analyser (InoDiag, La
Ciotat, France) at 365 nm after successive light exposure at 365 and 480 nm for 0.2 ms each; arbitrary unit values (AUV)
were automatically allotted for each spot using data-processing Analarray 4.4-1 software (InoDiag). The ﬁrst reading (a) at
365 nm allowed for determination of the area of each spot and for screening for the presence of all bacterial antigens: 1,
Staphylococcus aureus; 2, IgM; 3, IgG; 4, double-stranded DNA; 5, Mycoplasma pneumoniae; 6, Coxiella burnetii; 7,
Chlamydophila pneumoniae; 8, Chlamydia psittaci; 9, Francisella tularensis; 10, Legionella pneumophila serotype 1; 11,
L. pneumophila serotype 2; 12, L. pneumophila serotype 3; 13, L. pneumophila serotype 4; 14, L. pneumophila serotype 5; 15,
L. pneumophila serotype 6. The second reading at 470 nm was superimposed on the view obtained at 365 nm; ﬂuorescence
within a deﬁned area was converted to a grey-scale pixel image for detection and quantiﬁcation of IgG (b).The third
reading at 594 nm was automatically processed as described above for 470 nm, but was used to detect and quantify IgM
(c). This ﬁgure represents a serum positive for acute Q-fever with IgG spot number 6 (b) and IgM spot number 6 (c).
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or slide inversion) or because washes were not
satisfactory. Sera were tested with other slides
without problems. The control spots included on
the slides allowed the detection of rheumatoid
factor in 18 sera and antinuclear antibodies in eight
sera.
Cut-off establishment
The InoDiag assay was evaluated using a panel of
88 single serum samples obtained from patients
with acute pneumonia and 160 controls. Three cut-
offs were deﬁned in pixels for each antigen in
ﬂuorescence values. With the ﬁrst cut-off, serum
was considered to be positive for Coxiella burnetii
phase II when IgG >1500 and IgM >7500, for
F. tularensis when IgG >5500 and IgM >12 000,
for M. pneumoniae when IgM >5000, for C. pneu-
moniaewhen IgG >500, for Chlamydia psittaciwhen
IgG >3000, and for L. pneumophila when
IgG >3000. Results obtained with the InoDiag
assay were compared with those obtained with
the the reference techniques to assess their corre-
lation. A signiﬁcant correlation (p < 0.0001) be-
tween manual IFA and automated IFA was noted
for Coxiella burnetii IgG ⁄ IgM detection, and for
F. tularensis IgG ⁄M detection, with Pearson coef-
ﬁcients of 0.57 ⁄ 0.32 and 0.68 ⁄ 0.71, respectively. A
signiﬁcant correlation (p <0.0001) was noted be-
tween ELISA and automated IFA for M. pneumo-
niae IgM detection, with a Pearson coefﬁcient of
0.63, without consideration of an age limit, and
0.71 with consideration of a 30-year age limit. No
signiﬁcant correlation was noted between the
automated and manual IFA for C. pneumoniae
and Chlamydia psittaci (p 0.0003) and for L. pneu-
mophila (p 0.0009); the Pearson coefﬁcients were
0.24 and 0.22, respectively.
Performance of the InoDiag assay
Using the three cut-off values, sera were classiﬁed
into four groups for each antigen: negative, low
positive, positive, and very positive. For each cut-
off, sensitivity, speciﬁcity, PPV and NPV were
calculated (Table 1).
The ﬁrst cut-off yielded the best performance
for sensitivity. The diagnostic sensitivity was
deﬁned as the fraction of patients correctly diag-
nosed using the InoDiag assay, and a single
serum sample from among the patients diagnosed
using the reference techniques.
In the 23 cases of acute Q-fever, IgM was
detected with a sensitivity of 100%. All the 16
cases of tularaemia were diagnosed, with a
sensitivity for IgM and IgG detection of 100%.
Only nine of the 11 cases of C. pneumoniae and
Chlamydia psittaci infections were detected (sen-
sitivity 77%). Only 12 cases of L. pneumophila
infection were diagnosed (66%). In all of
the ten cases of M. pneumoniae infection, IgM
Table 1. Performance of the InoDiag method compared to
our reference techniques
Pathogen Se (%) Sp (%) PPV (%) NPV (%)
Coxiella burnetii
Cut-off 1
IgG 71 100 100 97
IgM 100 100 100 100
Cut-off 2
IgG 71 95 55 97
IgM 71 100 100 97
Cut-off 3
IgG 33 100 100 94
IgM 28 100 100 94
Mycoplasma pneumoniae
£30 years old
Cut-off 1
IgM 100 98 66 100
Cut-off 2
IgM 66 100 100 98
Cut-off 3
IgM 33 100 100 97
Without age limit
Cut-off 1
IgM 66 94 50 97
Cut-off 2
IgM 66 100 100 98
Cut-off 3
IgM 33 100 100 97
Francisella tularensis
Cut-off 1
IgG 100 95 69 100
IgM 100 100 100 100
Cut-off 2
IgG 66 100 100 96
IgM 60 100 100 97
Cut-off 3
IgG 44 100 100 96
IgM 40 100 100 96
Chlamydophila pneumoniae and Chlamydia psittaci
Cut-off 1
IgG 88 94 31 99
Cut-off 2
IgG 55 99 83 98
Cut-off 3
IgG 22 100 100 97
Legionella pneumophila
Cut-off 1
IgG 63 98 44 99
Cut-off 2
IgG 66 99 66 99
Cut-off 3
IgG 66 100 100 99
The cut-offs were deﬁnite in pixels for each antigen in ﬂuorescence value. The 3
InoDiag cut-off values were chosen in order to have the best sensitivity (Se) and
negative predictive value (NPV) for the ﬁrst cut-off value and the best speciﬁcity
(Sp) and positive predictive value (PPV) for the third cut-off value. The medium
cut-off value was chosen to select a grey zone. We calculated the Se, Sp, PPV and the
NPV based on the all 248 samples using our routine technique (manual IFA and
ELISA) as reference, compared to the InoDiag method for each antigen.
Sensibility, speciﬁcity and predictive positive and negative values were determined
for the 3 InoDiag cut-off compared to our reference techniques, IFA for C. burnetii; F.
tularensis, L. pneumophila, C. pneumoniae and C. psittaci, ELISA for M. pneumoniae.
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was detected, using a 30-year age limit. Without
this limit, only ten of the 19 cases were diag-
nosed.
The speciﬁcity of the InoDiag assay was 100%
for Coxiella burnetii (IgM and IgG detection) and
100% for F. tularensis (IgM detection). One hun-
dred and ﬁfty-two of the 160 control sera tested
negative for F. tularensis IgG (95%). For C. pneu-
moniae and Chlamydia psittaci, 150 of the 160
control sera tested negative for IgG (94%).
Cross-reactions between C. pneumoniae and Chla-
mydia psittaci were noted. For L. pneumophila, 156
of the 160 control sera tested negative (98%).
Cross-reactions among the Legionella species were
noted. For M. pneumoniae, 156 of the 160 control
sera tested negative (98%). Overall, cut-offs 2 and
3 gave the best speciﬁcity (Table 2).
Reproducibility assay
The reproducibility of the InoDiag assay was
evaluated using sera tested in triplicate for each
antigen. Variation coefﬁcients of 10% for C. pneu-
moniae, 7% for Chlamydia psittaci, 10% for
M. pneumoniae, 3% for Coxiella burnetii, 6% for
L. pneumophila and 12% for F. tularensis were
calculated.
DISCUSSION
In the present study, the InoDiag assay was
evaluated with a panel of sera collected from
patients with acute pneumonia. Customary tech-
niques used at the Timone Hospital laboratory
were used as reference standards (Table 2). The
greatest advantage of this automated IFA is that
it allows performance of all 11 serological tests
with IgG and IgM titration in one step within
1 h. Except for the serum deposit and the slide
insertion into the reader, all the immunoﬂuores-
cence processes, including serum and conjugate
incubations and washes, are automated. A small
amount of serum (5 lL) was used because the
InoDiag assay is performed with a 1 : 16 serum
dilution. The reading process is automated and
the technician working time was reduced to
2 min, which was a great advantage in enabling
better organization of the laboratory workﬂow.
The technician required no particular experi-
ence, and the InoDiag assay minimized the
effects of human subjectivity and interhuman
variability. As controls are included in each
slide, there is no need for serum controls, and
rheumatoid factor and antinuclear antibody are
assayed systematically for each patient, which
facilitates the interpretation of false-positive
results. Also, automatic control of serum and
conjugate distribution for each slide allows the
detection of false-negative results. These four
controls improve the IFA quality and open a
new avenue for IFA standardization and repro-
ducibility.
The results show signiﬁcant correlation be-
tween InoDiag test and our reference technique
for Coxiella burnetii IgM detection, M. pneumoniae
IgM detection (when the age limit is set at
<30 years [20]) and for F. tularensis IgG and IgM
detection.
As the clinical diagnosis of Q-fever is difﬁcult,
its diagnosis in most instances relies upon serol-
ogy. Diagnosis based on a single sample is not
ideal; however, the presence of phase II IgM at
Table 2. Comparison of serological procedure InoDiag versus reference technique in the serodiagnosis of atypical
pneumonia
References techniques
InoDiag IFA ELISA
Technician time 5 min 2 h 2 h
Total amount antigens detected 11 1 1
Immunoglobulin G and M detection One step Two step One step
Serum volume 5 lL 10 lL 10 lL
Incubation process Automatized Manual Automatized
Washing process Automatized Manual Automatized
Reading process Automatized
20 sec
Absence of human subjectivity
One patient at time
Manual
5 min
Human subjectivity
One patient at time
Automatized
3 min
Absence of human subjectivity
96 patients at time
Controls Four internal controls:
-Serum distribution
-Rheumatoid factor detection
-Nuclear antibody
-IgG and IgM distribution
Negative and positive serum control Negative and positive
serum control
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a signiﬁcant titre using IFA is strong evidence of
Coxiella burnetii infection [21]. Considering its
performance, the InoDiag serological assay ap-
pears to be as appropriate for IgM screening as
previously described ELISA tests [22–24].
However, the InoDiag assay revealed only
phase II antigens in the course of Q-fever in a
patient with risk factors for chronic Q-fever;
phase I antigens should then be searched for
during follow-up.
Currently, IFA is the reference technique for
Q-fever diagnosis [25], and the InoDiag technol-
ogy described here offers the advantage of IFA
with automation. As for acute F. tularensis infec-
tion, because of the difﬁculty of culturing the
pathogen, most of the cases are diagnosed on
the basis of combined clinical and serological
ﬁndings.
Microagglutination and ELISA are the most
frequently used techniques [26,27], and the diag-
nosis is usually conﬁrmed by the demonstration
of an antibody response 2 weeks after the onset
of the disease. Microagglutination assay is less
sensitive than ELISA. In case of brucellosis and
yersiniosis, serology cross reaction has been
described [28,29].
The InoDiag assay uses immunoﬂuorescence,
and is very sensitive and speciﬁc. It could be an
alternative to ELISA. In the case of M. pneumo-
niae respiratory tract infection, IgM antibodies
require up to 1 week, and sometimes longer, to
reach diagnostic titres [20]. Serology is an
important tool for the diagnosis, partly because
of the ease of collecting the sample, but PCR is
increasingly being used for this diagnosis [30,31].
The speciﬁcity of IgM quantiﬁcation varies
according to the diagnostic detection kit used
[20,32] and the age of the patient [33,34]. In
young patients, a single elevated IgM titer could
indicate an acute infection, but a seroconversion
is more speciﬁc [34].
For the diagnosis of M. pneumoniae infection,
direct evidence of the pathogen can be obtained
by using PCR [31]. As the InoDiag assay shows
good IgM detection, a single sera testing could be
used as the doctor’s test for the point of care or in
epidemiological study.
The InoDiag assay did not show any signiﬁcant
correlation with reference methods for C. pneu-
moniae, Chlamydia psittaci and L. pneumophila IgG
detection. In the case of acute C. pneumoniae
respiratory infection, serological testing is most
commonly used [35]. Direct identiﬁcation of
C. pneumoniae by PCR is showing increased
promise for rapid diagnosis, but this method
requires standardization [35]. The lack of well-
standardized and validated commercial tests is
responsible for discordant and controversial sero-
logical [36] and PCR results [35].
IFA is the current reference standard for the
serological diagnosis of many bacterial diseases
[37]; however, the lack of standardization of IFA
has been deplored [38]. Automated ELISA, which
is more standardized and less subjective, has been
used in this study, and the InoDiag assay may be
a good reference method.
In the case of acute L. pneumophila infection,
L. pneumophila serogroup 1 antigen detection in
urine is recommended, and the use of a serolog-
ical test is controversial. The ﬁrst serological
testing is usually negative, and a second serum
testing is needed to conﬁrm the diagnosis of
legionellosis.
High IgG titres during the early phase have
been interpreted as being of diagnostic value but,
at best, show a low PPV [3]. The performance of
the InoDiag assay was comparable to those of the
methods reported in the literature [39–41]. IFA
and ELISA are the most commonly used methods,
with ELISA being generally preferred because of
its lower subjectivity and better reproducibility
[42]. The negative InoDiag assay performances
may be due to the lack of reproducibility of IFA.
However, this multiplexed IFA test could be an
alternative to ELISA [42] for serodiagnosis in
epidemic areas.
These results highlight the place of multi-
plexed serological testing in acute atypical pneu-
monias where serological specimens are easiest
to collect. This technique is efﬁcient for primary
serological screening for acute Coxiella burnetii
and F. tularensis infections. For these two patho-
gens, diagnosis is frequently based only on
serology, because of the difﬁculty in cultivating
and manipulating these bacteria. For C. pneumo-
niae, M. pneumoniae and Chlamydia psittaci, the
InoDiag assay could be interesting for epidemi-
ological studies. It is adaptable to the prevalence
and incidence of the disease in the population,
using the three cut-off values with different
sensitivity and speciﬁcity. This InoDiag automa-
tion avoids the subjectivity of IFA. With more
evaluation, this will open the way for a complete
standardization of IFA.
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